<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024255</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-4000-CL-203</org_study_id>
    <nct_id>NCT03024255</nct_id>
  </id_info>
  <brief_title>A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brickell Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brickell Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety and efficacy of 3 concentrations of
      BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the
      Safety and Efficacy of 3 concentrations of Topically Applied BBI-4000 in Subjects with
      Axillary Hyperhidrosis.

      Safety will be assessed through collection of vital signs, adverse events, local skin
      responses, hematology, serum chemistry laboratory testing and urinalysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperhydrosis severity questionnaire</measure>
    <time_frame>6 Weeks</time_frame>
    <description>An 11 question evaluation tool to assess the effect of BBI-4000 5%, 10% and 15 % gel on hyperhidrosis disease severity measure when applied topically in subjects with axillary hyperhidrosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events, local tolerability assessments, vital signs and laboratory tests</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of the safety and local tolerability of 3 concentrations of BBI-4000 gel when applied topically in subjects with axillary hyperhidrosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gravimetric sweat production</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Measured weight of the amount of sweat produced</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>BBI-4000 Concentration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-4000 Concentration 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-4000 Concentration 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-4000 Concentration 1</intervention_name>
    <description>Lowest test dose</description>
    <arm_group_label>BBI-4000 Concentration 1</arm_group_label>
    <other_name>BBI-4000 Low Concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-4000 Concentration 2</intervention_name>
    <description>Test dose between high and low concentrations</description>
    <arm_group_label>BBI-4000 Concentration 2</arm_group_label>
    <other_name>BBI-4000 Medium Concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-4000 Concentration 3</intervention_name>
    <description>Highest test dose</description>
    <arm_group_label>BBI-4000 Concentration 3</arm_group_label>
    <other_name>BBI-4000 High Concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (Placebo)</intervention_name>
    <description>Vehicle without drug</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject ≥ 18 years of age.

          -  Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a)
             symptoms of hyperhydrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4, (c)
             HDSS of 3 or 4 and (d) a minimum GSP of 50 mg is each axilla with a combined total of
             at least 150 mg.

          -  The ability to understand and follow all study-related procedures including study drug
             administration.

          -  Sexually active female of childbearing potential (FOCBP)* must agree to periodic
             pregnancy testing and use a medically acceptable method of contraception while
             receiving protocol-assigned product.

        Exclusion Criteria:

          -  In the Investigators opinion, any skin or subcutaneous tissue conditions of the
             axilla(s).

          -  Prior use of any prohibited medication(s) or procedure(s) within the specified
             timeframe for the treatment of axillary hyperhidrosis.

          -  Anticholinergic agents used to treat conditions such as, but not limited to,
             hyperhidrosis, asthma, incontinence, gastrointestinal cramps, and muscular spasms by
             any route of administration.

          -  Use of potent inhibitors of cytochrome P450 CYP3A and CYP2D6.

          -  Use of any cholinergic drug (e.g. bethanechol) within 30 days.

          -  Known cause of hyperhidrosis or known history of a condition that may cause
             hyperhidrosis (i.e., hyperhidrosis secondary to any known cause such hyperthyroidism,
             diabetes mellitus, medications, etc.).

          -  Subjects with unstable diabetes mellitus or thyroid disease, history of renal or
             hepatic impairment, malignancy glaucoma, intestinal obstructive or motility disease,
             obstructive uropathy, myasthenia gravis, BPH, neurological or psychiatric conditions,
             Sjögren's or Sicca syndrome, or cardiac abnormalities that may alter or exacerbate
             sweat production by the use of anticholinergics in the investigator's opinion.

          -  Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of
             the components of the topical formulation.

          -  Subject is pregnant, lactating or is planning to become pregnant during the study.

          -  History or presence of supraventricular tachycardia, ventricular arrhythmias, atrial
             fibrillation or atrial flutter.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence A Romel, MS</last_name>
    <role>Study Director</role>
    <affiliation>Brickell Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IHHS Call Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sweat gland disease</keyword>
  <keyword>sweating</keyword>
  <keyword>underarm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

